Evotec launched the Innovation Centre for Fragment Based Drug Discovery (FBDD) that will offer an alternative approach for identifying novel, small molecule hits for a number of biological targets.
The company has established a scientific board for this Innovation Centre to advise on the selection of high-quality biological targets for Evotec's pipeline of projects for partnering. The board will also advise on the development of these programs and identify areas to further enhance the technology base.
Fragments are difficult to detect due to their weak interactions with protein target, Evotec explains. The company thus implemented a unique fragment screening platform, EVOlution, capable of identifying low molecular weight fragments in a biologically relevant environment.